2. IntroductionNeonatal lupus erythematosus (NLE) refers to a
clinical spectrum ofcutaneous, cardiac, and systemic abnormalities
observed in newborninfants whose mothers have auto antibodies
against Ro/SSA, La/SSB,and, less commonly, U1-ribonucleoprotein
(U1-RNP). The conditionwas first described in 1954 by McCuistion
and Schoch who reported acase of transient lupus skin lesion in an
infant with an ANA-positivemother. The most common presentation is
a nonscarring,nonatrophic skin lesion which resemble subacute
cutaneous lupuserythematosus. The infants may have no skin lesions
at birth butdevelop them during the first weeks of life. Cardiac,
hematological,hepatobiliary, central nervous, and pulmonary systems
may also beinvolved. The condition is usually benign and
self-limited butsometimes may be associated with serious
sequelae.2Prof Ariyanto Harsono MD PhD SpA(K)
3. PathophysiologyA number of studies have suggested that NLE
is caused bythe transplacental passage of maternal
autoantibodies.These autoantibodies may cause damage to
thedeveloping tissue and increase the risk of bearinginfants with
NLE. Approximately 98% of affected infantshave maternal transfer of
autoantibodies againstRo/SSA, La/SSB, and, less commonly,
U1-RNP.However, only 1-2% of mothers with theseautoantibodies have
neonates with NLE, regardless ofwhether the mothers are symptomatic
or not3Prof Ariyanto Harsono MD PhD SpA(K)
4. The 52-kD Ro/SSA (Ro52) ribonucleoprotein is anantigenic
target strongly linked with the autoimmuneresponse in mothers whose
children haveNLE, congenital heart block, and other
conductionabnormalities. Anti-Ro52/SSA autoantibodiesantagonize the
serotonin-induced L-type calciumchannel activation on human fetal
atrial cells andtrigger an inflammatory response, leading
ultimately tofibrosis and scarring of the atrioventricular node,
sinusnode, and His bundle. This may explain theelectrophysiological
abnormalities in NLE and thepathogenesis of the cardiac rhythm
disturbances, whichmay lead to diminished cardiac output and
thesubsequent development of congestive heart failure.4Prof
Ariyanto Harsono MD PhD SpA(K)
5. In a rat model, Boutjdir et al. demonstrated that
IgGcontaining anti-Ro/SSA and -La/SSB antibodies inducescomplete AV
block in beating hearts and in multicellularpreparations, thus
implicating a preferential interactionof these autoantibodies with
calcium channels and/orassociated regulatory proteins. This is
consistent withthe observed inhibition of calcium channels that
maybe a critical factor contributing to the pathogenesis ofcomplete
heart block. These conduction defects arecaused by anti-Ro/SSA and
anti-La/SSB antibodies aswell as other autoantibodies against
cardiacadrenoceptors and muscarinic acetylcholine receptors.5Prof
Ariyanto Harsono MD PhD SpA(K)
6. The antibodies associated with heart block andwith cutaneous
disease are believed to bedifferent; antibodies against the
52/60-kDRo/SSA and 48-kD La/SSB ribonucleoproteinsare associated
with heart block, whereasantibodies against the 50-kD
La/SSBribonucleoprotein are associated withcutaneous disease.6Prof
Ariyanto Harsono MD PhD SpA(K)
7. 7Prof Ariyanto Harsono MD PhD SpA(K)antibodies against the
50-kD La/SSB ribonucleoprotein are associated with cutaneous
disease
8. On the other hand, anti-U1RNP autoantibodies are
usuallyassociated with atypical cutaneous lesions without cardiac
orsystemic abnormalities in a small number of NLE cases andmay play
a role in the pathogenesis of thrombocytopenia. Ithas been
demonstrated that the anti-U1RNP antibody frompatients with
connective tissue disease can directly recognizea variety of
antigens on the endothelial surface of thepulmonary artery,
including the components of U1RNP orother unknown polypeptides.
These results suggest thatbinding to HPAECs of this autoantibody
may be one of thetriggers of endothelial cell inflammation in
various connectivetissue diseases. The spectrum of cutaneous
disease in U1RNPantibody-positive infants is similar to Ro/SSA
antibody-positive infants with NLE. Complete heart block was not
afeature of U1RNP antibody-positive NLE.8Prof Ariyanto Harsono MD
PhD SpA(K)
9. It has been shown that the amount of maternalantibodies,
rather than their presence, is associatedwith fetal tissue injury.
However, only some neonatesexposed to these antibodies develop
complications.Therefore, other factors such as titers of
maternalantibodies, genetic predisposition, and
environmentalfactors such as viral infection may be
involved.Additionally, induction of apoptosis in
culturedcardiomyocytes has been demonstrated to result in
theexpression of Ro/La antigens on the cell surface forrecognition
by circulating maternal antibodies. It isspeculated that in vivo
such opsonized apoptoticcardiocytes promote an inflammatory
response byresident macrophages with damage to
surroundingconducting tissue.9Prof Ariyanto Harsono MD PhD
SpA(K)
10. 10Prof DR Dr Ariyanto Harsono SpA(K)Maternal antibodies,
genetic predisposition, and environmental factors such as viral
infectionmay be involved.
11. In addition to its presence in the skin and heart, the
Roantigen is also found in theliver, bowel, lungs, brain, and blood
cellsthe tissuesthat are most often affected by NLE.
Ultravioletradiation and estrogens increase Ro antigen expressionon
the surface of the keratinocyte. Although ultravioletradiation can
induce or exacerbate the skin lesions, it isnot required for their
development. Because of limitedopportunity for solar exposure in
neonates and younginfants, photosensitivity is more commonly seen
afterphototherapy for neonatal hyperbilirubinemia.11Prof Ariyanto
Harsono MD PhD SpA(K)
12. photosensitivity is more commonly seen after phototherapy
for neonatalhyperbilirubinemia12Prof Ariyanto Harsono MD PhD
SpA(K)
13. EpidemiologyNLE is a rare acquired autoimmune disease that
occurs in 1 of every20,000 live births in the USA . Elsewhere,
epidemiology is usuallydescribed in small case series. The presence
of certain majorhistocompatibility complexes such as human
leukocyte antigen B8and human leukocyte antigen DR3 in the mother
predisposes theinfant to NLE and congenital heart block. Although
there is noapparent racial predilection, disparity in outcomes
betweenminorities and whites has been observed. Like many
autoimmunediseases, reports from the Research Registry for Neonatal
Lupus/USindicate that the female-to-male ratio is approximately 2:1
withcutaneous NLE, but the gender distribution for cardiac disease
isapproximately equal . The risk of NLE or congenital heart
blockdeveloping in a woman who tests positive for Ro/SSA who has
neverhad a child with NLE or congenital heart block is less than
1%.13Prof Ariyanto Harsono MD PhD SpA(K)
14. Many seropositive mothers with anti-Ro/SSA and anti-La/SSB
antibodies give birth to infants who do not showsigns and symptoms
of NLE. However, in those whohave had an infant with NLE, the risk
of cardiac and/orskin disease for a future pregnancy is high.
Theincidence of congenital heart block is 1530% in infantswith NLE.
Heart block usually develops in uterobetween the 18th and 24th
weeks of pregnancy. Infantsborn to mothers with hypothyroidism due
to thyroidautoantibodies and anti-Ro/SSA positivity are at
ninetimes higher risk of developing congenital completeheart block
than infants born to mothers with only anti-Ro/SSA
positivity.14Prof Ariyanto Harsono MD PhD SpA(K)
15. Approximately 4060% of mothers are asymptomaticwhen the
infants are diagnosed to have NLE. Theremaining mothers may have
SLE, Sjgrensyndrome, rheumatoid arthritis, or
undifferentiatedautoimmune disorder. Mothers with primarySjgren
syndrome or undifferentiated autoimmunesyndrome have a greater risk
of delivering an infantwith congenital complete heart block than
thosewith SLE. There is no association with paternalautoimmune
diseases.15Prof Ariyanto Harsono MD PhD SpA(K)
16. Clinical ManifestationsThe most common clinical
manifestations of NLE are, indecreasing order offrequency,
dermatologic, cardiac, and hepaticabnormalities. Some infants may
also havehematologic, neurologic, or splenic abnormalities. Oneor
more systems may be involved. Wisuthsarewong etal. performed a
retrospective study to review clinicalmanifestations on 17 patients
(10 girls and 7 boys) withNLE seen at the Department of Pediatrics,
SirirajHospital from 1993 to 2008.Cutaneous, cardiac,
hepatobiliary, and hematologicalinvolvement was found in 70.6%,
64.7%, 52.9%, and35.3% of infants, respectively.16Prof Ariyanto
Harsono MD PhD SpA(K)
17. Cutaneous lesions may be present at birth but often
appearwithin the first few weeks of life. Annular erythematous
orpolycystic plaques with or without fine scales characterizeNLE
and appear predominately on the scalp, neck, or face(typically
periorbital in distribution), but similar plaques mayappear on the
trunk or extremities. The dermatitis resemblesthe rash of subacute
cutaneous lupus erythematosus ratherthan the malar rash of SLE.
Periorbital erythema, referred toas raccoon eye or owl eye, is a
very commoncharacteristic. At times, the lesions may be
urticarial,desquamative, ulcerative, or crusted. Bullous lesions
may beseen with a particular predilection for the soles of the
feet.17Prof Ariyanto Harsono MD PhD SpA(K)
18. 18Prof Ariyanto Harsono MD PhD SpA(K)The dermatitis
resembles the rash of subacute cutaneous lupus erythematosus rather
than the malar rash ofSLE
19. Periorbital erythema, referred to as raccoon eye or owl
eye, is a verycommon characteristic19Prof Ariyanto Harsono MD PhD
SpA(K)
20. Bullous lesions may be seen with a particular predilection
for the soles of thefeet.20Prof Ariyanto Harsono MD PhD SpA(K)
21. Cutaneous involvement was characterized as
erythematouspatches (91.7%), subacute cutaneous lupus
erythematosuslesions (50%), petechiae (41.7%), persistent cutis
marmorata(16.7%), and discoidal lesions (8.3%). In some infants,
solarexposure seems to precipitate the eruption. These
lesionstypically last for weeks or months and then
resolvespontaneously consequent to the disappearance of
maternalantibodies in the neonatal circulation. Active
erythematouslesions after the first year of life should be
suspect.Dyspigmentation is frequent but usually
resolvesspontaneously. Atrophic lesions and, rarely, atrophic scars
maydevelop. The atrophic telangiectatic changes are mostevident
near the temples and scalp and do not necessarilyoccur in the same
sites as the erythematous lesions. Thelatter site may occasionally
be associated with a permanentalopecia. Telangiectasia, scarring,
and atrophic changes areexpected to persist. 21Prof Ariyanto
Harsono MD PhD SpA(K)
22. Cutaneous involvement was characterized as erythematous
patches (91.7%)22Prof Ariyanto Harsono MD PhD SpA(K)
23. The cardiac manifestations include conduction
abnormalities(first-, second-, and third-degree heart block)
andcardiomyopathy. Third-degree heart block, onceestablished, is
usually irreversible. Congenital heart blockmay present as
bradycardia noted in utero or duringphysical examination at birth.
Conduction disturbances mayalso present as irregular heartbeat and
prolongation of theQT interval. Congenital heart block may be
associated withendocardial fibroelastosis and cardiomyopathy. In
somecases, myocarditis and pericarditis can develop which maylead
to bradycardia. Heart failure is a well-recognizedcomplication
during the neonatal period.23Prof Ariyanto Harsono MD PhD
SpA(K)
24. The clinical pictures of hepatobiliary involvement maytake
the forms of elevation of liver enzymes (suchas aspartate
aminotransferase and alanineaminotransferase) and/or
conjugatedhyperbilirubinemia occurring a few weeks ormonths after
birth and resolving thereafter. Someinfants may have mild
hepatomegaly and, lesscommonly, splenomegaly. The hepatomegaly
andsplenomegaly are usually transient. Cholestatichepatitis and
hepatic failure may also occur.24Prof Ariyanto Harsono MD PhD
SpA(K)
25. Hematologic disturbances (e.g., hemolyticanemia,
thrombocytopenia, and neutropenia) mayoccur in the first 2 weeks of
life. Infants withhematological involvement are usually
asymptomatic.Autoantibodies, mainly anti-Ro, bind directly to
theneutrophil and cause neutropenia. Thrombocytopeniamay manifest
as petechiae. Hematologic symptomsusually appear at around the
second week of life anddisappear by the end of the second
month.Lymphopenia is a relatively common finding in adultswith SLE
but is not a characteristic hematologicabnormality of NLE. 25Prof
Ariyanto Harsono MD PhD SpA(K)
26. Other abnormalities such as hydrocephalus andmacrocephaly
may occur. Aseptic meningitis andmyelopathy have rarely been
reported. Pneumonitismay manifest as tachypnea and/or
tachycardia.26Prof Ariyanto Harsono MD PhD SpA(K)
27. Diagnosis and Differential DiagnosisThe diagnosis is
usually established based on theclinical features and the
demonstration of NLE-associated antibodies in the serum of the
mother orthe affected infant. NLE can mimic many
conditions.Differential diagnosis of NLE includes
seborrheicdermatitis, atopic dermatitis, neonatal acne,
tineacorporis, psoriasis, granuloma annulare, erythemamultiforme,
Langerhans cellhistiocytosis, congenital rubella,
congenitalsyphilis, Bloom syndrome, and
Rothmund-Thomsonsyndrome.27Prof Ariyanto Harsono MD PhD SpA(K)
28. Laboratory InvestigationsNLE is associated with the
anti-Ro/SSA antibody in more than 90% of patients.Occasionally,
patients only have anti-La/SSB or anti-U1RNP antibodies. Screening
ofinfants with NLE for the presence of these antibodies is strongly
recommended.Many asymptomatic mothers have positive putative
antibodies during pregnancy.As such, these mothers of patients
suspected of having neonatal lupuserythematosus should be screened
for antinuclear, anti-double-stranded DNA, anti-Ro/SSA,
anti-La/SSB, and anti-U1-RNP antibodies, irrespective of their
symptoms orclinical status. As anti-Ro/SSA antibodies can be
detected in one in 200 pregnantwomen, the risk for an
anti-Ro/SSA-positive woman to have an infant with NLE isrelatively
low. On the other hand, high anti-Ro/SSA levels correlate with the
risk ofcardiac complications. Serial prenatal
ultrasonography/electrocardiography shouldtherefore be performed on
pregnant women with high anti-Ro titers (50U/mL).Prenatal
ultrasonography may help identify NLE that affects the heart.28Prof
Ariyanto Harsono MD PhD SpA(K)
29. 29
30. Echocardiography may reveal various types ofstructural
deformities in the heart; combinedelectrocardiography and 24-hour
Holter monitoringmay reveal various cardiac conduction disorders
ordifferent types of heart blocks.Laboratory investigations may
revealpancytopenia, thrombocytopenia, leukopenia, orelevated
transaminase level.31Prof Ariyanto Harsono MD PhD SpA(K)
31. Skin biopsy is useful in patients with NLE when the
diagnosis isin doubt. Histologic examination shows
interfacedermatitis, keratinocyte damage, moderatehyperkeratosis,
follicular plugging, and vacuolar degenerationin the basal cell
layer. Epidermal atrophy may be found.Inflammatory infiltrate may
be intense with bulla formationhistologically. An immunofluorescent
examination reveals agranular deposition of immunoglobulin G (IgG)
at thedermoepidermal junction; IgM and C3 deposition may also
beevident.Skin biopsy is not pathognomonic. Various inflammatory
andinfectious conditions may show similar histological features.In
typical cases of NLE and positive autoantibodies, skinbiopsy is not
mandatory to confirm the diagnosis.32Prof Ariyanto Harsono MD PhD
SpA(K)
32. Skin Biopsy33Prof DR Dr Ariyanto Harsono SpA(K)Histologic
examination shows interfacedermatitis, keratinocyte damage,
moderatehyperkeratosis, follicular plugging, and
vacuolardegeneration in the basal cell layer. Epidermalatrophy may
be found. Inflammatory infiltratemay be intense with bulla
formationhistologically.
33. Treatment and Follow upNeonates with NLE should be managed
at a tertiarycare center. Multidisciplinary team involvementmay
also be indicated. Patients with NLE withcardiac involvement
require regular monitoring toassess cardiac function and the need
for apacemaker. A pacemaker is often necessary forthose who are
unable to compensate for a slowheart rate. Serial echocardiography
to monitor for aprolonged PR interval should also be arranged.
Ifthe cardiac involvement is severe, activity may haveto be
restricted in the young child.34Prof Ariyanto Harsono MD PhD
SpA(K)
34. Sunscreens may be useful in the treatment of cutaneous
lupuserythematosus, but a neonate is less likely to be exposed
tosunlight excessively. Nevertheless, solar exposure should
beavoided if possible. Parents should be advised to apply
sunscreenwell before solar exposure and to use a sunscreen with a
high SPFthat provides a broad-spectrum (UV-A) coverage which is
waterresistant. Behavior modification to include solar avoidance
shouldbe encouraged. Protective clothing is highly desirable.
Strategiesaimed at preventing disease before irrevocable scarring
ensues area high priority. Skin lesions of NLE can be treated with
mild topicalcorticosteroids. Anti malarial agents have potential
toxicity and aslow onset of action that their use in the treatment
of thistransient condition is probably not indicated. Laser therapy
may beconsidered for residual teleangiectasia.35Prof Ariyanto
Harsono MD PhD SpA(K)
35. Systemic corticosteroids and immunosuppressive agentsare
generally not indicated in the treatment of NLE.Children with NLE
need continued follow up, especiallybefore adolescence and if the
mother herself has anautoimmune disease. Although the child may not
be atincreased risk of developing SLE, the development ofsome form
of autoimmune disease in early childhoodmay be of concern.Infants
with severe hepatic and hematologicalinvolvement may require
treatment with systemiccorticosteroids, intravenous immunoglobulin,
and/orimmunosuppressive agents .Prof Ariyanto Harsono MD PhD SpA(K)
36
36. PrognosisThe morbidity and mortality of SLE of childhood
depend on the organsystems affected. Children with NLE have an
excellent long-termoutcome when only skin lesions are present. The
cutaneous lesionsusually disappear by 6 months of age coincident
with the clearance ofmaternal antibodies from the childs
circulation. Involvement of theskin may, rarely, lead to scar
formation. Although children withcutaneous disease may be more
prone to develop SLE orautoimmunity later in life, this is mainly
due to their geneticpredisposition, not that they had NLE. Their
non affected siblings arealso at risk for development of SLE or
autoimmunity. While thecutaneous lesions of NLE are themselves
benign, cutaneous NLE isassociated with a 610-fold risk for a
subsequent child with cardiacNLE.37Prof Ariyanto Harsono MD PhD
SpA(K)
37. NLE with cardiac involvement is associated with a 2030%
mortalityrate in the neonatal period. Mortality is particularly
high in casesof congenital heart block with concurrent
cardio-myopathy.Death most often results from congestive heart
failure caused bycongenital heart block. Approximately 57 to 66% of
patients withcongenital heart block eventually require a pacemaker.
Thosewith pacemakers are at risk of developing dilated
cardio-myopathy in their lives. Deaths may also occur later in life
as aresult of the failure of the pacemaker. However, many
childrenwith congenital heart block may be relatively asymptomatic
untiladolescence, when they begin to exercise. At that time, they
maydevelop syncope and require a pacemaker implantation.38Prof
Ariyanto Harsono MD PhD SpA(K)
38. The recurrence rate of congenital heart block is low, about
15%, butthis is nearly three times higher than the risk for
congenital heartblock in a primigravida with the putative
antibodies. Prospectiveclinical trials on use of antenatal
fluorinated steroids in womenwith anti-SSA/Ro and/or anti-SSB/La
antibodies and fetuses withheart block identified in utero are
required before definitiverecommendations can be made. A number of
anecdotal casessupport the use of dexamethasone for treatment of
hydrops andpossibly incomplete block.Most patients with NLE
affecting liver or blood have transient diseasethat spontaneously
resolves within 46 months. In somecases, cholestatic hepatitis and
liver failure may occur which isassociated with a poor prognosis.
Anemia, thrombocytopenia, andneutropenia are self-limited. However,
if severe thrombocytopeniais present, internal bleeding can lead to
a poor prognosis.39Prof Ariyanto Harsono MD PhD SpA(K)
39. Future PregnanciesAlthough the fetal disease is called
neonatal lupuserythematosus, this is considered a misnomer since
only about25% of mothers actually fulfill criteria for the
diagnosis of SLE.Furthermore, asymptomatic mothers do not
invariably become ill.Mothers of infants with NLE, particularly
infants with congenitalheart block, have a 2-fold to 3-fold
increased risk of having anaffected infant in a subsequent
pregnancy. On the other hand, therisk for an unselected
anti-Ro/SSA-positive woman has beenestimated at 1-2%. A prospective
controlled study of pregnancyoutcome in 100 women with autoimmune
diseases and anti-Ro/SSA antibodies showed that the prevalence of
congenital heartblock in newborns of prospectively followed up
women alreadyknown to be anti-Ro/SSA positive and with known
connectivetissue disorders was 2%.40Prof Ariyanto Harsono MD PhD
SpA(K)
40. In mothers with anti-Ro/SSA and/or anti-La/SSBantibodies
and infants with congenital heart block, therisk of recurrence in
subsequent offspring is 1725%.Therefore, carefully monitoring of
subsequentpregnancies with serial ultrasonography
andechocardiography, particularly at 1824 weeksgestation, is
essential. Intravenous immunoglobulinmerits evaluation as a
potential prophylactic approachin mothers who have previously had
an affected child.However, two studies failed to demonstrate
benefit inoutcome from intravenous immunoglobulin. On theother
hand, the use of hydroxychloroquine forpatients with SLE has been
associated with a lowerrate of NLE during pregnancy.41Prof Ariyanto
Harsono MD PhD SpA(K)
41. Shinohara et al. assessed the possibility of preventing
cardiac orcutaneous manifestations of NLE or treating the fetus
withcongenital heart block by administering corticosteroid therapy
tothe mother. Eighty seven offspring of 40
anti-Ro/SSA-positivemothers, followed up from 1979 to 1996, were
evaluated. None of26 neonates whose mothers received corticosteroid
maintenancetherapy initiated before 16 weeks gestation
demonstratedcongenital heart block, whereas 15 of 61 neonates whose
mothersreceived no corticosteroids during pregnancy or began
receivingsteroid therapy after 16 weeks gestation had congenital
heartblock. Complete congenital heart block, once developed, did
notrespond to corticosteroid treatment in utero. Four infants
whosemothers received corticosteroid treatment before 16
weeksgestation had skin lesions of NLE.42Prof Ariyanto Harsono MD
PhD SpA(K)
42. Once established, complete congenital heart blockwas
irreversible, and maternal corticosteroidtherapy did not
effectively prevent cutaneous LE.However, prenatal maintenance
therapy withprednisolone or betamethasone given to themother
starting early in pregnancy (before 16weeks gestation) might reduce
the risk ofdeveloping antibody-mediated congenital heartblock in
the offspring.Prof Ariyanto Harsono MD PhD SpA(K) 43
43. Mothers with SLE should be treated with drugs that are
effective andsafe for the fetus. Such an approach may diminish or
reduce theprevalence of complete heart block associated with NLE.
Tincani etal. recently reported increased occurrence of learning
disabilities inchildren born to mothers with SLE. Corticosteroids
and someimmunosuppressive drugs can be used in pregnancy to
controlmaternal disease. Some data suggest that prolonged fetal
exposureto dexamethasone may impair cerebral development. On the
otherhand, Tincani et al. followed 6 children (age range,
1465months), born to patients treated with dexamethasone because
ofcongenital heart block. These children were found to have a
normalintelligence quotient . However, the authors remarked
thatinformation about long-term outcome of children exposed
toimmunosuppressive drugs in utero are still lacking, and
moreefforts are needed in this research area.44Prof Ariyanto
Harsono MD PhD SpA(K)
44. SummaryNeonatal lupus erythematosus (NLE) refers to
aclinical spectrum of cutaneous, cardiac, andsystemic abnormalities
observed in newborn infantswhose mothers have autoantibodies
against Ro/SSAand La/SSB. The condition may be associated
withserious sequelae. Neonates with NLE should bemanaged at a
tertiary care center, andmultidisciplinary team involvement may
beindicated.45Prof Ariyanto Harsono MD PhD SpA(K)